Fig. 3 | Signal Transduction and Targeted Therapy

Fig. 3

From: Exploratory phase II trial of an anti-PD-1 antibody camrelizumab combined with a VEGFR-2 inhibitor apatinib and chemotherapy as a neoadjuvant therapy for triple-negative breast cancer (NeoPanDa03): efficacy, safety and biomarker analysis

Fig. 3

Pre-NAT serum IL-18 and biopsy PD-L1 levels predict the response to NAT. a Comparison of pre-NAT serum protein levels between pCR patients and non-pCR patients. b Comparison of post-NAT serum protein levels between the pCR and non-pCR patients. c The amount of protein that significantly changed in the serum between pCR patients and non-pCR patients. d Venn diagram showing altered protein intersections before and after NAT. e, f Compared with non-pCR patients, pCR patients had higher IL-18 expression before and after treatment. g ROC curve assessing the accuracy of the pre-NAT serum IL-18 level for treatment response. h pCR patients had higher PD-L1 levels in biopsy samples before treatment than non-pCR patients did. i No significant difference in pretreatment serum IL-18 levels between different biopsy PD-L1 staining scores. j Treatment response in patients with different biopsy PD-L1 staining scores. k Biopsy PD-L1 staining scores of patients with different treatment responses. l ROC curve evaluating the pretreatment response predictive (PRP) score’s accuracy for treatment response prediction. m Formula for the PRP score. n Treatment response in patients stratified by high vs. low PRP scores. o Percentages of different biopsy PD-L1 staining scores in PRPscore-high and PRPscore-low patients. [0,1): 0 ≤ PD-L1 score<1, [1,10):1 ≤ PD-L1 score<10, [10,100): 10 ≤ PD-L1 score<100; *P < 0.05, **P < 0.01

Back to article page